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Abstract
Background: Intolerance to enteral nutrition is common in critically ill adults, and may result in significant
morbidity including ileus, abdominal distension, vomiting and potential aspiration events. Prokinetic agents are
prescribed to improve gastric emptying. However, the efficacy and safety of these agents in critically ill patients is
not well-defined. Therefore, we conducted a systematic review and meta-analysis to determine the efficacy and
safety of prokinetic agents in critically ill patients.
Methods: We searched MEDLINE, EMBASE, and Cochrane Library from inception up to January 2016. Eligible
studies included randomized controlled trials (RCTs) of critically ill adults assigned to receive a prokinetic agent or
placebo, and that reported relevant clinical outcomes. Two independent reviewers screened potentially eligible
articles, selected eligible studies, and abstracted pertinent data. We calculated pooled relative risk (RR) for dichotomous
outcomes and mean difference for continuous outcomes, with the corresponding 95 % confidence interval (CI). We
assessed risk of bias using Cochrane risk of bias tool, and the quality of evidence using grading of recommendations
assessment, development, and evaluation (GRADE) methodology.
Results: Thirteen RCTs (enrolling 1341 patients) met our inclusion criteria. Prokinetic agents significantly reduced
feeding intolerance (RR 0.73, 95 % CI 0.55, 0.97; P = 0.03; moderate certainty), which translated to 17.3 % (95 % CI 5,
26.8 %) absolute reduction in feeding intolerance. Prokinetics also reduced the risk of developing high gastric residual
volumes (RR 0.69; 95 % CI 0.52, 0.91; P = 0.009; moderate quality) and increased the success of post-pyloric feeding tube
placement (RR 1.60, 95 % CI 1.17, 2.21; P = 0.004; moderate quality). There was no significant improvement in the risk of
vomiting, diarrhea, intensive care unit (ICU) length of stay or mortality. Prokinetic agents also did not significantly
increase the rate of diarrhea.
Conclusion: There is moderate-quality evidence that prokinetic agents reduce feeding intolerance in critically ill
patients compared to placebo or no intervention. However, the impact on other clinical outcomes such as pneumonia,
mortality, and ICU length of stay is unclear.
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Background
Delayed gastric emptying is common in critically ill
patients as a result of many factors including medica-
tions (e.g., narcotics, catecholamines), hyperglycemia,
renal dysfunction, mechanical ventilation, or the disease
process itself [1–5]. When gastric emptying was mea-
sured in critically ill patients, 46 % of them had evidence
of delayed gastric emptying [6]. Untreated slow gastric
emptying has a plethora of clinical consequences such as
vomiting, aspiration of gastric contents, pneumonia, and
inadequate provision of calories [7–12]. Studies have
shown an association between feeding intolerance, pro-
longed intensive care unit (ICU) stay, and increased risk
of death [12, 13]. Although it is possible that this associ-
ation is a reflection of the underlying severity of illness
or a consequence of other unmeasured confounders,
feeding intolerance could be playing a causal role.
Despite these risks, enteral feeding is preferred to
parenteral nutrition as it is associated with fewer sep-
tic complications, lower risk of bacterial translocation,
and is cheaper [14–21]. There are several therapeutic
options that help to overcome feeding intolerance.
Enteral nutrition via a small bowel feeding tube may
reduce the risk of pneumonia, without compromising
nutrition delivery [22]; however, small bowel feeding
tubes require technical expertise and are not always
available. Prokinetic agents are used for treating non-
critically ill patients with gastroparesis [6–8]. The use of
these agents in the ICU, although common, is based on
unclear evidence.
Metoclopramide, erythromycin and domperidone are
the commonest prokinetic agents. Metoclopramide is
a selective D2 (dopamine) receptor antagonist that
enhances peristalsis in the upper gastrointestinal (GI)
tract [23]. Domperidone is another D2 receptor antagonist
that increases the amplitude of esophageal motor function
and duodenal contractions, and coordinates peristalsis
across the pylorus to accelerate gastric emptying [24].
Erythromycin acts locally to enhance the release of motilin
from enterochromaffin cells of the duodenum. Motilin
causes contraction of the duodenum and gastric antrum
[24]. These agents have all been shown to prolong the QT
interval, and may cause serious arrhythmias [25].
The most recent systematic review in this area was
published more than a decade ago [26]. Since then,
multiple randomized trials have been published [27–31].
In addition, cisapride has been withdrawn from the mar-
ket due to increased risk of arrhythmia and death [32].
Moreover, authors did not focus on clinical outcomes and
incorporated studies using acetaminophen absorption as a
surrogate marker for gastric motility [33–36]. Our study is
an up-to-date systematic review and meta-analysis of
randomized trials aiming to determine the efficacy of
prokinetic agents use in critically ill adults.
Methods
Study selection
Studies were eligible if: (1) the study design was a
parallel-group randomized controlled trial (RCT); (2) the
population included adult critically ill patients admitted
to the ICU who received enteral nutrition; (3) the inter-
vention group received a prokinetic agent, either dom-
peridone, metoclopramide, or erythromycin, regardless
of the dose, frequency, and duration; (4) the control
group received either no intervention or a placebo; and
(5) the outcomes included any of the following: mortal-
ity, aspiration, pneumonia, ICU length of stay, vomiting,
diarrhea, high gastric residual volume (GRV), feeding
intolerance, post-pyloric feeding tube placement, or
malignant arrhythmia. We excluded RCTs that compared
prokinetic agents, and studies that did not report clinical
outcomes.
For our purposes, feeding intolerance was defined as
either GRV ≥150 ml, vomiting, or abdominal distention
resulting in feeding interruption. For pneumonia out-
come we did not mandate meeting a specific definition;
there is no universally accepted definition of ventilator-
associated pneumonia. Mortality was restricted to
mortality in the ICU or hospital mortality. A successful
feeding tube insertion was one that was radiologically or
endoscopically confirmed to be post-pyloric, in any
segment of the duodenum or jejunum.
Search strategy
We searched MEDLINE, EMBASE, and the Cochrane
Library from inception until January 2016. The search
strategy is detailed in Additional file 1: Table S1. We
screened citations of all potentially eligible articles with-
out language or publication date restrictions. Two re-
viewers screened titles and abstracts to identify articles
for full review, and evaluated the full text of potentially
eligible studies. In addition, reviewers screened the refer-
ence list of review articles for additional studies. Disagree-
ments between reviewers were resolved by consensus, and
if necessary, consultation with a third reviewer.
Data extraction
Two reviewers independently used a predesigned data
abstraction form to extract patients’ demographic data,
and data on interventions, outcomes, risk of bias, and
other relevant information. Disagreements were resolved
by discussion and consensus. We contacted study au-
thors for missing or unclear information.
Risk of bias
Two reviewers independently assessed trials for risk of
bias using the Cochrane risk of bias tool [37]. For each
included trial, we judged articles as low, unclear, or high
risk of bias for the domains of adequate sequence
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generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment,
incomplete outcome data, selective outcome reporting,
and for other bias. The overall risk of bias for each in-
cluded trial was categorized as low if the risk of bias is
low in all domains, unclear if the risk of bias was unclear
in at least one domain and with no high risk of bias
domain, or high if the risk of bias was high in at least one
domain. We resolved disagreements by discussion and
consensus.
Statistical analysis
We analyzed data using RevMan software (Review
Manager, version 5.3. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014). We used the
DerSimonian and Laird random-effects model to pool the
weighted effect of estimates across all studies [38]. We es-
timated study weights using the inverse variance method.
We calculated pooled relative risk (RR) for dichotomous
outcomes and mean differences (MD) for continuous out-
comes, with a corresponding 95 % confidence interval
(CI). We inspected funnel plots to assess for publication
bias [39].
Heterogeneity and subgroup analysis
We assessed statistical heterogeneity using the Chi2 and
I2 statistics. We considered Chi2 < 0.1 or I2 > 50 % as sig-
nificant heterogeneity [40]. We explored heterogeneity
between studies by performing predetermined subgroup
analyses to investigate whether certain factors influenced
treatment effect. These subgroups included: feeding in-
tolerance and GRV definitions (GRV >250 ml vs GRV
>150 ml), class of agents used (metoclopramide vs
erythromycin), and subgroup analysis by risk of bias
(low risk vs unclear or high risk).
Results
Characteristics of included studies
Our initial search identified a total of 637 citations. After
removing duplications 476 publications remained. Of
those, 51 underwent a full text review. Another 38 were
then excluded for a variety of reasons (Additional file 1:
Table S2). Thirteen studies met the inclusion criteria
and were included in the quantitative analysis [27–31,
41–48] (Fig. 1). The details of eligible trails are presented
in Table 1. A total of 1341 patients were enrolled in 13
RCTs that included a variety of critically ill patients with
medical, surgical, and neurosurgical conditions. Eight
trials used intravenous (IV) metoclopramide at different
frequencies. Seven RCTs used erythromycin at a range
of doses and administration schedules. Two studies used
domperidone, one of which did not indicate the dose,
route of administration, or frequency. Other details of
eligible studies are presented in Table 1.
Fig. 1 Preferred reporting items for systematic reviews and
meta-analyses (PRISMA) flow chart. Description of the study
selection process
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Table 1 Characteristics of studies
Author Population Feeding
intolerance at
baseline
Intervention groups Outcomes Definition of
feeding
intolerance
Definition of
nosocomial
pneumonia
Funding
Whatley
1984
USA
(n = 10)
Critically ill patients who failed
post-pyloric tube insertion
Mean age: 46.0 years, 80.0 % male
Mean APACHE II score: not reported
No Metoclopramide 20 mg
IV single dose
vs
no intervention
1) Successful post-pyloric
feeding tube insertion
N/A N/A NR
Heiselman
1995
USA
(n = 105)
Critically ill patients who
required enteral nutrition
Mean age: NR
% male: NR
Mean APACHE II: NR
No Metoclopramide 10 mg IV
vs
no medication
1) Successful post-pyloric
feeding tube insertion
N/A N/A NR
Kalliafas
1996
USA
(n = 57)
Critically ill patients who required
enteral nutrition
Mean age: 57.4 years, 52.6 % male
Mean APACHE II score 14.9
No Erythromycin 200 mg IV
vs
placebo
1) Successful post-pyloric
feeding tube insertion
N/A N/A NR
Paz 1996
USA
(n = 83)
Critically ill patients who required
enteral nutrition
Mean age: 60.8 years, 53.0 % male
Mean APACHE II score: NR
No Erythromycin 200 mg
IV single dose
vs
metoclopramide 10 mg
IV single dose
vs
placebo
1) Successful postpyloric
feeding tube insertion
N/A N/A Industry
Chapman
2000
Australia
(n = 20)
Critically ill, mechanically ventilated
patients who failed enteral feeding
Mean age: 46.3 years, 80 % male
Mean APACHE II score:16.2
Yes Erythromycin 200 mg
IV single dose
vs
placebo
1) Mortality
2) Feeding intolerance
Gastric residual volume
greater than or equal
to 250 ml
N/A NR
Yavagal
2000
India
(n = 305)
Critically ill patients who required
a nasogastric tube for more than
24 hours
Mean age: 36.5 years, 62.0 % male
Mean APACHE II score: 17.7
No Metoclopramide 10 mg
IV q8h
vs
placebo
1) Mortality
2) Nosocomial pneumonia
N/A 1) New infiltrate of chest
radiograph
2) A positive tracheal or
sputum culture
3) Axillary temperature
greater than 38 °C
4) Leukocytosis (white
cell count greater than
12,000/ml) or Leukopenia
(white cell count less than
3000/ml)
NR
Pinilla
2001
Canada
(n = 80)
Critically ill patients who required
enteral nutrition for 3 or more days
Mean age: 52.9 years, 55.0 % male
Mean APACHE II score: NR
No Metoclopramide, cisapride
or domperidone (no dose/
route/frequency provided)
vs
no intervention
1) Gastrointestinal
intolerance
2) Vomiting
3) Gastric residual volumes
4) Diarrhea
1) Witnessed vomiting
2) Diarrhea (3 or more liquid
stools in a 24-hour period)
3) Gastric residual volume
greater than 150 ml for
the control group or
greater than 250 mL
for the treatment group
N/A NR
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Table 1 Characteristics of studies (Continued)
Berne
2002
USA
(n = 68)
Critically ill trauma patients who
had a gastric residual volume
greater than 150 ml in the 1st
48 hours of feeding
Mean age: 37.1 years, 84.7 % male
Mean ISS: 24.2
Yes Erythromycin 250 mg IVq6h
vs
placebo
1) Nosocomial pneumonia
2) Feeding intolerance
3) ICU length of stay
4) Mortality
5) Infectious complications
Gastric residual volumes
greater than 150 ml
1) Fever greater than 38.6 °C,
2) Leukocytosis (white blood
cells greater than 10,000 cell/L)
3) Purulent sputum
4) New infiltrate on chest
radiograph
5) Sputum sample showing
moderate or many white
blood cells and a positive
culture
NR
Reignier
2002
France
(n = 40)
Critically ill patients receiving
mechanical ventilation and
early nasogastric feeding
Mean age: 68.0 years, 50.0 % male
Mean APACHE II score: NR
No Erythromycin 250 mg
IV q6h × 5 days
vs
D5W 50 ml IV q6h × 5 days
1) Mortality
2) Gastric intolerance
3) Vomiting
1) Vomiting
2) Gastric residual volume
greater than 250 ml
N/A NR
Griffith
2003
USA
(n = 36)
Critically ill patients requiring
enteral nutrition and exhibiting
one or more of: evidence of delayed
gastric emptying with repeatedly
high gastric aspirates, history of
pulmonary aspiration of tube feeds,
clinical high risk of aspiration,
head-of-the-bed elevation not
possible, or severe acute pulmonary
disease
Mean age: 57.2 years, 69.4 % male
Mean APACHE II score: NR
Yes Erythromycin 500 mg
IV single dose
vs
placebo
1) Successful post-pyloric
feeding tube insertion
N/A N/A Academic
Nursal
2007
Turkey
(n = 19)
Critically ill patients
Mean age: 43.4 years, 84.2 % male
Mean APACHE II: 12.9
Metoclopramide
10 mg IV TID × 5 days
vs
normal saline TID × 5 days
1) Mortality
2) Aspirations
3) Feeding intolerance
4) ICU length of stay
5) Vomiting
6) Ileus
7) Diarrhea
8) Gastric residual volume
9) Extrapyramidal
movement
1) Gastric residue volume
greater than twice the
current hourly infusion
rate, or if it was more
than 150 ml
2) Abdominal distention,
vomiting, or diarrhea
N/A NR
Nassaj
2010
(n = 220)
Critically ill patients who required
a nasogastric tube for more than
24 hours
Mean age: 44.0 years, 65.5 % male
Mean APACHE II score: 14.9
No Metoclopramide
10 mg PO q8h × 5 days
vs
no intervention
1) Nosocomial pneumonia
2) Mortality
N/A 1) Axillary temperature greater
than 37.5 °C
2) Leukocytosis (white
blood cells greater than
11, 000 cell/L)
3) Increase in tracheal
secretions (>0.4 cm3/hour)
4) New infiltrate on the chest
radiograph or progression
of an existing infiltrate
NR
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Table 1 Characteristics of studies (Continued)
Hu 2015
China
(n = 298)
Critically ill patients who required
enteral nutrition for more than 3 days
Mean age: 62.9 years, 66.1 % male
Mean APACHE II score: 21.1
No Metoclopramide
20 mg IV (single dose)
vs
domperidone 20 mg QID
vs
no intervention
1) Successful post-pyloric
feeding tube insertion
N/A N/A Academic
APACHE acute physiology, age and chronic health evaluation, ICU intensive care unit, IV intravenous, N/A not applicable, NR not reported, PO per os, QID four times a day, TID three times a day
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Risk of bias
Using the Cochrane risk-of-bias tool, we judged two
studies to be at high risk of bias due to inappropriate
randomization and blinding methods [30, 48], five
studies were at low risk of bias [29, 31, 43–45], and
we were not able to comprehensively assess risk of
bias in six studies due to lack of information [27, 28,
41, 42, 46, 47]. The details of risk of bias assessment
are presented in Fig. 2.
Publication bias
We inspected funnel plots for each outcome for asym-
metry; however, we included fewer than 10 RCTs in each
outcome, therefore, the test is underpowered to reliably
detect evidence of publication bias (Additional file 1:
Figures S1 and S2).
Main outcomes
The use of prokinetic agents significantly reduced feed-
ing intolerance, as assessed by five studies enrolling 227
patients (RR 0.73, 95 % CI 0.55, 0.97; P = 0.03; I2 = 0 %)
(Fig. 3). The number needed to treat (NNT) was 12
(95 % CI 7, 111). In addition, prokinetics significantly re-
duced the risk of developing high GRV (RR 0.69, 95 %
CI 0.52, 0.91; P = 0.009; I2 = 0 %) (Fig. 4). Prokinetics sig-
nificantly increased the rate of successful post-pyloric
feeding tube placement (RR 1.60, 95 % CI 1.17, 2.21; P =
0.004; I2 = 46 %) (Fig. 5). Compared to placebo, proki-
netic agents did not prevent the development of pneu-
monia (RR 1.00, 95 % CI 0.76, 1.32; P = 0.57; I2 = 0 %)
(Fig. 6), nor reduced the risk of death (RR 0.97, 95 % CI
0.81, 1.16; P = 0.72; I2 = 0 %) (Additional file 1: Figure
S3) or length of ICU stay (RR 1.24, 95 % CI −5.21, 7.68,
P = 0.43; I2 = 0 %) (Additional file 1: Figure S4). However,
there was a non-significant reduction in vomiting with
the use of prokinetic agents (RR 0.74, 95 % CI 0.49, 1.12,
P = 0.15; I2 = 0 %) (Additional file 1: Figure S5). Finally,
prokinetics did not significantly increase the risk of diar-
rhea compared to placebo (RR 1.82, 95 % CI 0.67, 4.91;
P = 0.24; I2 = 0 %) (Additional file 1: Figure S6).
Subgroup analysis
Despite the absence of statistical heterogeneity, we per-
formed subgroup analyses to determine if there are im-
portant subgroup differences. Subgroup analysis by
threshold of GRV (>150 ml vs >250 ml) was not signifi-
cant (Additional file 1: Figure S7). Prokinetic agents did
not prevent feeding intolerance in patients without gas-
troparesis (RR 0.62, 95 % CI 0.31, 1.22, P = 0.16), but did
reduce feeding intolerance in those with pre-existing
gastroparesis (RR 0.70, 95 % CI 0.52, 0.96; P = 0.03),
however, the interaction test did not reach statistical sig-
nificance (Additional file 1: Figure S8). Although the
treatment effect on feeding intolerance was larger in
trials with high risk of bias (RR 0.65, 95 % CI 0.44,
0.96; P = 0.03) the interaction test was not significant
(Additional file 1: Figure S9). Similarly, there was no
significant subgroup difference in any outcomes by drug
class, except for erythromycin, which improved feeding in-
tolerance (Additional file 1: Figure S10). We present the
Fig. 2 Risk of bias assessment. Summary of risk of bias in individual
randomized controlled trials in this systematic review; green circles
low risk of bias, yellow circles unclear risk of bias, red circles indicate
high risk of bias
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results of our subgroup analyses in Additional file 1:
Table S3.
Quality of evidence
The quality of evidence was moderate for feeding in-
tolerance, high GRV, and success in post-pyloric tube
placement outcomes. While the quality of evidence was
low for other outcomes. The details of risk of bias and
quality assessment are outlined in Additional file 1:
Table S4 and S5, respectively.
Discussion
In this systematic review, we included 13 RCTs (1341
patients) in the final analysis. Our results show that the
use of prokinetic agents in patients receiving enteral
feeding in the ICU improve both feeding intolerance and
high GRVs. Furthermore, prokinetic agents were found
to increase the success of inserting post-pyloric feeding
tubes. Prokinetics did not significantly reduce the risk of
pneumonia, mortality, length of stay in the ICU, or
vomiting, nor did it increase the risk of diarrhea.
Many studies used acetaminophen absorption as a sur-
rogate for gastric motility [33, 35, 49–53] and were in-
cluded in prior systematic reviews [26]. Acetaminophen
is not absorbed by the stomach but is rapidly absorbed
in the intestine [54]. As a result of rapid absorption,
measurements such as time to peak acetaminophen con-
centration and maximum plasma concentration are used
to assess gastric motility [54]. Acetaminophen is a con-
venient test to use in critically ill patients as it simply re-
quires serial blood work. Although acetaminophen
absorption has been correlated with scintigraphy assess-
ments [54], the accuracy of the test is questioned. Stud-
ies show no significant correlation between the half-time
of gastric emptying and peak acetaminophen levels, and
therefore it may not correspond clinically [55, 56]. For
those reasons, we chose not to use the acetaminophen
absorption as a surrogate of feeding intolerance and fo-
cused on clinical outcomes.
As previously described, prokinetics are not without
potential complications. In the wake of cisapride being
withdrawn from the market due to risk of malignant
arrhythmia, intravenous erythromycin has been avoided
due to its potential to cause serious ventricular arrhythmia
[57, 58]. However, arrhythmia occurred at a dose of 3
grams per day, which far exceeds that used for the promo-
tility properties of the drug [27, 28, 41, 43, 48]. Although
arrhythmia was not explicitly reported in the RCTs used
in this meta-analysis, mortality did not significantly differ
between metoclopramide and erythromycin as demon-
strated by this systematic review. In addition to cardiac
complications, there is also concern about microbial re-
sistance to antibiotics [26]. Berne et al. specifically looked
at infectious complications, and found none [27]. Lastly,
tachyphylaxis can develop with erythromycin use. This
was observed in an RCT showing loss of erythromycin
Fig. 3 Feeding intolerance outcome. Forest plot includes pooled estimates for randomized controlled trials comparing prokinetic agents to
placebo or no intervention for feeding intolerance outcome. IV inverse variance, CI confidence interval
Fig. 4 High gastric residual volume (>250 ml). Forest plot includes pooled estimates for randomized controlled trials comparing prokinetic agents
to placebo or no intervention for high gastric residual volume outcome. IV inverse variance, CI confidence interval
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effect after 48 hours of treatment [27]. In another RCT,
there was reduction in GRVs at 12 hours, but not beyond
[41]. Likewise, another study found no difference in GRVs
between the erythromycin and placebo groups at day 5 of
the trial [48].
Domperidone is another prokinetic that can be consid-
ered and is commonly used in the outpatient setting to
treat gastroparesis. However, domperidone is associated
with risk of QT interval prolongation [23]. A case–con-
trol study of 1608 cases of cardiac arrhythmia and death
found there was an increased risk with domperidone use
in the outpatient setting, particularly with doses exceed-
ing 30 mg per day (odds ratio (OR) 11.4, 95 % CI 1.99,
65.2) [59]. Only two RCTs in our review used domperi-
done [29, 45]. In one study physicians were allowed to
use erythromycin, domperidone or metoclopramide as
their prokinetic to treat feeding intolerance and only one
patient received domperidone [29]. Therefore, we cannot
make firm conclusions about the efficacy of domperi-
done. However, domperidone did seem to be as effective
as metoclopramide for aiding the insertion of a post-
pyloric feeding tube [29].
The Canadian Critical Care Clinical Practice guidelines
recommend metoclopramide as the first-line prokinetic
agent in the ICU [60]. Several studies suggest that
erythromycin may be more effective than metoclopra-
mide [52, 61]. Our subgroup analysis was underpowered
to detect any meaningful difference between different
agents. The recent American Society of Parenteral and
Enteral Nutrition (ASPEN) guidelines suggest using ei-
ther metoclopramide or erythromycin in patients at high
risk of aspiration [62]. Both agents are associated with
tachyphylaxis [61, 63]. However, due to the risk of com-
plications of erythromycin, metoclopramide was pro-
posed as the first-line treatment. Moreover, we believe
that prokinetics should not be used prophylactically, but
only be used to treat patients with feeding intolerance,
this is supported by our subgroup analysis demonstrat-
ing larger effect in this population.
Prior meta-analysis examined the effects of prokinetics;
however, our study is the first to report on clinical out-
comes [26]. We conducted a comprehensive search and in-
cluded more RCTs, therefore, the results are more precise
and generalizable. Two independent reviewers performed
screening, data abstraction and risk of bias assess-
ment. In addition, we adhered to the PRISMA guidelines
(Additional file 1: Table S6) [64]. Finally, we used GRADE
methodology to assess the quality of evidence.
Despite the robust results, there are some limitations.
Important clinical outcomes (i.e., pneumonia, diarrhea,
and vomiting) were not consistently reported in all stud-
ies, which resulted in imprecise estimates. Moreover,
cardiac and infectious side effects were rarely reported
and many RCTs had a short follow-up time, therefore,
we could not generate meaningful estimates to help
practitioners. In addition, there was inconsistency in the
Fig. 5 Successful post-pyloric feeding tube placement. Forest plot includes pooled estimates for randomized controlled trials comparing
prokinetic agents to placebo or no intervention for successful insertion of post-pyloric tube outcome. IV inverse variance, CI confidence interval
Fig. 6 ICU-acquired pneumonia outcome. Forest plot includes pooled estimates for randomized controlled trials comparing prokinetic agents to
placebo or no intervention for ICU-acquired pneumonia outcome. IV inverse variance, CI confidence interval
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definition of feeding intolerance, and in some studies the
definition of feeding intolerance was not clear. Also, the
type, dose and frequency of prokinetic agents varied sig-
nificantly across studies. Last, we were unable to do sub-
group analysis on the different ICU patient populations
and to discern the outcomes in patients with vs without
sepsis. A large RCT is needed to examine any subgroup
effect, and to determine the impact on other clinical out-
comes, including potential side effects. However, the
current evidence supports the use of prokinetic agents
to treat feeding intolerance in critically ill patients, in
the absence of contraindication to these agents.
Conclusion
Moderate-quality evidence showed that prokinetic
agents are effective in improving feeding intolerance in
critically ill patients and in facilitating post-pyloric feed-
ing tube placement, and low-quality evidence failed to
demonstrate a significant reduction in pneumonia,
vomiting, or mortality. There was also no significant in-
crease in the rates of diarrhea, and no significant
arrhythmia was reported in eligible studies. Future RCTs
are needed to determine the most effective agent and
the impact other important outcomes.
Additional file
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intolerance outcome). Figure S2p. Funnel plot (high GRV). Figure S3
Mortality outcome. Figure S4 ICU length of stay outcome. Figure S5
Vomiting outcome. Figure S6 Diarrhea outcome. Figure S7 Subgroup
analysis by GRV threshold. Figure S8 Subgroup analysis by indication of
treatment. Figure S9 Subgroup analysis by risk of bias. Figure S10
subgroup analysis by drug class. (DOCX 2164 kb)
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